No Data
New stock news | Open up a new capital track for Hong Kong stocks 18A! Yiteng Pharmaceutical will conduct a stock swap reverse acquisition of GENOR-B (06998).
According to a disclosure by the Hong Kong Stock Exchange on April 15, GENOR-B (06998) has submitted a listing application to the Stock Exchange. Yiton Pharma has conducted a reverse acquisition of GENOR-B through a share swap, and after the merger, the company will be renamed "Yiton GENOR Pharmaceutical Group Limited."
GENOR-B (06998) announced its 2024 annual results, with a net loss of 52.974 million yuan, a year-on-year reduction of 92.2%.
GENOR-B (06998) released its 2024 annual performance, with a revenue of 0.206 billion yuan (Renminbi, the same below), ...
Express News | Genor Biopharma Holdings FY Revenue RMB 206.2 Million
GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
GENOR-B (06998.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui, on March 18, announced that GENOR-B (06998.HK) will hold a Board of Directors meeting on March 28, 2025 (Friday), to consider and approve the full year performance of the company and its subsidiaries for the year ending December 31, 2024, and its release.
GENOR-B: DATE OF BOARD MEETING
